Pharma and medtech companies have undergone unprecedented growth through aggressive M&A over the last decade, with average deal sizes increasing by 77% in 2023. Portfolio expansion can certainly ...

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...

Auditing pharmaceutical supply chains down to every last employee and pallet would be ideal, but is logistically impractical.

With the rise in global counterfeiting operations, stakeholders need to be aware of their responsibility when it comes to pharmaceutical goods and their legitimacy. Companies can make this task easier ...

For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

NHS Wales has signed a memorandum of understanding (MoU) with Illumina to expand an earlier partnership focusing on lung ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...